Phase I therapy study of 186re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck

Journal of Nuclear Medicine

Volumn 41, Issue 12, 2000, Pages 1999-2010

  Colnot, D R ^a   Quak, J J ^a   Roos, J C ^a   Van Lingen, A ^a   Wilhelm, A J ^a   Van Kamp, G J ^a   Huijgens, P C ^a   Snow, G B ^a   Van Dongen, G A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

186Re; Dosimetry; Head and neck cancer; Monoclonal antibodies; Pharmacokinetics; Radioimmunotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MONOCLONAL ANTIBODY; RHENIUM 186;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; ISOTOPE LABELING; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOIMMUNOTHERAPY; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; BONE MARROW; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RECOMBINANT FUSION PROTEINS; RHENIUM; THROMBOCYTOPENIA;

EID: 0034519646     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Head and neck cancer
2. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
3. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-1abeled anti-CD20 antibody and autologous stem-cell rescue
4. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
5. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131-I-labeled chimeric monoclonal antibody G250
6. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab′)2
7. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
8. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody
9. EGS4 Monte Carlo determination of the beta dose kernel in water
10. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies
11. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials
12. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response
13. Rhenium-186-labeled chimeric antibody NR-LU-13: Pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
14. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer
15. Selection of monoclonal antibody FA8 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients
16. Clinical screening of monoclonal antibodies 323/A3, cSF-25, and K928 for suitability of targeting tumors in the upper aerodigestive and respiratory tract
17. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform
18. MAb U36: A novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck
19. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa
20. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas
21. CD44 variant exon epitopes in primary breast cancer and length of survival
22. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins
23. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor
24. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
25. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumor ceils are expressed in normal tissues of humans and cynomolgus monkeys
26. Construction and characterization of the chimeric monoclonal antibody F48 for therapy of head and neck cancer
27. High dose rhenium-186 labeling of monoclonal antibodies for clinical application: Pitfalls and solutions
28. 186Re using the MAG3 chelate for radioimmunotherapy of cancer: A technical protocol
29. Dosimetry of rhenium-186-labeled monoclonal antibodies: Methods, prediction from technetium-99m-labeled antibodies and results of phase I trials
30. Considerations for imaging Re-188 and Re-186 isotopes
31. Estimation of absolute organ activity using five different methods of background correction
32. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body
33. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
34. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: Reconstruction of a theoretical phantom of the larynx for radiation dose calculation of local tissues
35. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts
36. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients
37. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer